Fig. 3
From: Vaccination with nanoparticles combined with micro-adjuvants protects against cancer
Formulating CuMVTT-p33 nano-vaccine with the micron-sized MCT adjuvant induces significant p33 specific T cell response and enhances cytokines secretion. a Vaccination scheme for six vaccine groups, CuMVTT-VLPs, CuMVTT-Actin, CuMVTT-p33, CuMVTT-p33 admixed with CpG 1668, CuMVTT-p33 formulated with MCT and CuMVTT-p33 formulated with Alum. b Percentage of CD8+ Tetramer+ CTLs (means ± SEM) in the spleen in each vaccinated group. c Percentage of CD8+ IFN-γ+ secreting cells (means ± SEM) in the spleen in each vaccinated group. d Percentage of CD8+ TNF-α+ cells (means ± SEM) in the spleen in each vaccinated group. e Percentage of CD8+ IFN-γ+/TNF-α+ secreting cells (means ± SEM) in the spleen in each vaccinated group. Statistical analysis by Oneway ANOVA (Turkey’s Multiple Comparison Test). f Representative flow cytometry dot plots showing the percentage of CD8+ Tetramer+ CTLs in each vaccinated group. g Representative flow cytometry dot plots showing the percentage of CD8+ IFN-γ+/TNF-α+ secreting cells in each vaccinated group. (3 mice per group), one representative of 3 similar experiments is shown